ABSTRACT
In this report, we describe a rare case: deep vein thrombosis due to May-Thurner syndrome with a spontaneous pelvic extraperitoneal hematoma. This unique challenge highlights balancing thrombosis treatment and bleeding risk. Endovascular treatment with delayed anticoagulation may be an alternative to surgery for stable retroperitoneal hematoma in May-Thurner syndrome patients.
Subject(s)
Anticoagulants , Hematoma , May-Thurner Syndrome , Venous Thrombosis , Humans , Hematoma/etiology , Hematoma/diagnostic imaging , Hematoma/therapy , May-Thurner Syndrome/diagnostic imaging , May-Thurner Syndrome/therapy , May-Thurner Syndrome/complications , Anticoagulants/therapeutic use , Anticoagulants/adverse effects , Treatment Outcome , Venous Thrombosis/diagnostic imaging , Venous Thrombosis/etiology , Venous Thrombosis/therapy , Computed Tomography Angiography , Female , Phlebography/methods , Endovascular Procedures , Male , Middle Aged , Retroperitoneal SpaceABSTRACT
Germinated brown rice (GBR) flours were prepared by hammer milling and jet milling. The effect of the milling on the physicochemical and pasting properties of the resultant flours were investigated. The jet milling of GBR resulted in flour with different particle sizes, which were air-classified into coarse and fine size fractions. As the particle size decreased, the amount of damaged starch increased. The WAI, WSI, and oil absorption of the jet-milled GBR flour was slightly lower than that of the hammer-milled flour. Increased α- and ß-amylase activities were observed in the coarse fraction of the jet-milled GBR flour compared with the hammer-milled and jet-milled fine fractions. The RVA viscosity profiles of the fine fraction of the jet-milled GBR flour were significantly higher than those of the hammer-milled or the coarse fraction of the jet-milled GBR flour. Compared with the hammer-milled flour, jet milling increased in vitro starch hydrolysis.
Subject(s)
Flour/analysis , Oryza/metabolism , Amylases/metabolism , Germination , Hydrolysis , Oryza/growth & development , Particle Size , Solubility , Starch/chemistry , Starch/metabolism , Viscosity , Water/chemistryABSTRACT
Aspirin has been used for decades for the primary and secondary prevention of cardiovascular disease (CVD). The effect of aspirin in secondary prevention is well-known but is still debatable for primary prevention. Despite the controversy, aspirin is believed to have a beneficial effect in primary prevention and has been widely used. However, whether the doubts concerning the wide use of aspirin are correct has resulted in the publication of data from several large clinical trials recently. There are several clinical guidelines from various international organizations on the use of aspirin for the primary prevention of CVD, and they offer some conflicting recommendations. A reduction in the overall incidence of CVD with the development of modern prevention therapies has weakened the impact of aspirin in primary prevention. Large randomized clinical trials have found decreased or no difference in CVD events but a significant increase in the risk of bleeding. Taking aspirin for the primary prevention of CVD is no longer recommended, especially for patients who have a low to moderate risk. An assessment of the balance between the benefits and risks of aspirin use should be considered.
